Control of hypertension in coronary heart disease

Insights

Out-of-office blood pressure control in coronary heart disease (CHD) patients is significantly better than in-office readings. Ambulatory blood pressure monitoring (ABPM) reveals higher hypertension control rates, offering a more accurate patient assessment.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Preventive Medicine

Background:

  • Investigates out-of-office hypertension control in coronary heart disease (CHD) patients using 24-h ambulatory blood pressure monitoring (ABPM).
  • Utilizes data from the Spanish Society of Hypertension ABPM Registry, encompassing a large network of primary care physicians.
  • Compares out-of-office BP control with traditional in-office measurements in treated essential hypertensive patients with CHD.

Discussion:

  • Out-of-office hypertension control (46.4%) significantly exceeded in-office control (28.7%) in 2434 treated CHD patients.
  • Identified 'office resistance' in 25.2% of patients, characterized by normal ambulatory BP but elevated office BP despite treatment.
  • Highlights the discrepancy between office and ambulatory BP measurements in assessing hypertension control.

Key Insights:

  • Ambulatory blood pressure monitoring (ABPM) provides a more accurate assessment of hypertension control in CHD patients compared to office BP.
  • A substantial proportion of patients exhibit 'office resistance,' masking true BP control status.
  • Current hypertension management strategies may overestimate control based solely on office readings.

Outlook:

  • Further efforts are required to optimize BP control in CHD patients.
  • Physicians can be reassured by potentially better BP control than previously estimated from office data.
  • Recommends the integration of ABPM for a more comprehensive understanding of hypertension management in CHD.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...